DelveInsight’s Dermatomyositis Market Insights report includes a comprehensive understanding of current treatment practices, dermatomyositis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the Dermatomyositis Market Report
Discover which therapies are expected to grab the major dermatomyositis market share @ Dermatomyositis Market Insight
Dermatomyositis is a rare inflammatory disease with distinctive cutaneous findings and varying degrees of systemic involvement; it can occur in both juvenile and adult forms. Adult and juvenile dermatomyositis share pathognomic skin rash and muscle inflammation, but they are distinct diseases with unique disease features and complications.
While the clinical presentation of JDM differs from that of adults, the skin lesions are similar, except for an increased incidence of calcinosis cutis in juvenile patients. Low-grade fever, an increased risk of gastrointestinal manifestations, and symmetric arthritis of the large and small joints are all common findings.
The underlying cause of dermatomyositis is unknown; however, evidence suggests that genetic, immune, and environmental factors all play a role. A detailed patient history, thorough clinical examination, detection of characteristic physical findings, and certain specialized tests are used to make the diagnosis. Creatinine kinase levels are less likely to be elevated in JDM than in adult dermatomyositis.
Dermatomyositis Epidemiology Segmentation
The dermatomyositis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
Download the report to understand which factors are driving dermatomyositis epidemiology trends @ Dermatomyositis Epidemiological Insights
Dermatomyositis Treatment Market
The goal of dermatomyositis treatment is to decrease inflammation and vasculitis, as well as to reduce symptomatology and improve the patient’s quality of life. To accomplish this goal, a dermatomyositis treatment regimen must be initiated early in the disease process and will necessitate an interprofessional approach to therapy. The administration of steroids is used to treat dermatomyositis. A high prednisolone dose must also be started early to improve muscle weakness. Steroid therapy should relieve symptoms within 4 weeks, after which the steroid dosage should be gradually tapered to 1 mg/kg every other day over a 10-week period. When prednisone is not an option, second-line agents such as methotrexate and azathioprine may be used.
Patients who develop resistance to therapy may benefit from rituximab, IVIG, and other biologics . Antipruritics, topical steroids, hydroxychloroquine, and steroids may be used to treat superficial skin diseases. The FDA approved OCTAGAM 10% , a 10% solution of intravenous human immunoglobulin (IVIG), to treat adults with diabetes last year. The approval was based on the findings of the Progress in Dermatomyositis (ProDERM) study. More recently, the FDA Office of Orphan Product Development granted Octapharma, the manufacturer of OCTAGAM 10%, 7 years of marketing exclusivity for this product, which is the first and only IVIG treatment for adult dermatomyositis.
To know more about dermatomyositis treatment guidelines, visit @ Dermatomyositis Treatment Scenario
Dermatomyositis Pipeline Therapies and Key Companies
Learn more about the FDA-approved drugs for dermatomyositis @ Drugs for Dermatomyositis Treatment
Dermatomyositis Market Dynamics
The dynamics of the dermatomyositis market is anticipated to change in the future due to the improvement in the rise in the number of healthcare spending across the world and rising cases of dermatomyositis . Moreover, There has been a significant increase in knowledge and understanding of diabetes in recent years, which is increasingly being considered when making therapeutic decisions . Better prognostic markers would allow physicians to diagnose and treat at the onset of disease, potentially preventing disease progression. In addition, R&D to understand the diversity of the disease may improve diagnosis.
Scope of the Dermatomyositis Market Report
Discover more about dermatomyositis drugs in development @ Dermatomyositis Clinical Trials
Table of Contents
1. Dermatomyositis Market Key Insights
2. Dermatomyositis Market Report Introduction
3. Dermatomyositis Market Overview at a Glance
4. Dermatomyositis Market Executive Summary
5. Disease Background and Overview
6. Dermatomyositis Treatment and Management
7. Dermatomyositis Epidemiology and Patient Population
8. Patient Journey
9. Dermatomyositis Marketed Drugs
10. Dermatomyositis Emerging Drugs
11. Seven Major Dermatomyositis Market Analysis
12. Dermatomyositis Market Outlook
13. Potential of Current and Emerging Therapies
14. KOL Views
15. Dermatomyositis Market Drivers
16. Dermatomyositis Market Barriers
17. Unmet Needs
18. SWOT Analysis
20. DelveInsight Capabilities
22. About DelveInsight
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/consulting/conference-coverage-services